|
Published by: SMI Publishing, Ltd
Published: Jun. 18, 2007
Table of Contents
- Day One
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California.
- 9.10 NOVEL APPROACHES TO TREAT DEPRESSION
- Examining current approaches to drug development and research
- Disease overview
- Drug development and research
- Challenges & strategies
- Novel approaches as targets to treat the disease
- Lee E Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth.
- 9.50 EFFICIENT CLINICAL DEVELOPMENT OF ANTIDEPRESSANTS AND ANTIANXIETY AGENTS
- Current issues with clinical drug development
- Unmet needs in depression and anxiety arena
- Targets and animal models
- Translational issues
- Early signal of efficacy issues
- Novel study design approaches
- Dr Tanya Ramey, Clinical Lead, Neurosciences, Pfizer Global R&D.
- 10.30 Morning Coffee
- 11.00 STRATEGIES FOR THE DESIGN AND SYNTHESIS OF NEW TREATMENTS FOR DEPRESSION AND ANXIETY
- The design and synthesis of antidepressants based on the monoamine hypothesis of depression and the current status of the GABAA receptor modulators as potential treatment for anxiety disorders
- Drugs that interfere with the reuptake and/or metabolism of biogenic amines have been used to treat depression for more than 4 decades
- An important recent development has been the emergence of the triple uptake inhibitors (SNDRIs), which inhibit the reuptake of all three neurotransmitters most closely linked to depression: serotonin, norepinephrine, and dopamine
- Preclinical studies and clinical trials indicate that a drug inhibiting the reuptake of all three of these neurotransmitters may produce greater efficacy than traditional antidepressants (SSRIs, etc.)
- Design and synthesis of antidepressants based on the monoamine hypothesis of depression
- Current approaches on design and synthesis of GABAA receptor modulators as potential treatment for anxiety disorders
- Dr Zhengming (Jimmy) Chen, Senior Director of Chemistry, DOV Pharmaceuticals.
- 11.40 NOVEL NON-SEDATING ANXIOLYTICS - XY1029 AND XY2412
- GABA A receptor targets
- Beta 2,3 selective drugs - electrophysiology
- Racemic generic drug with anxiolytic acitivity
- Animal models
- Development path
- Dr Vincent F Simmon, President & CEO, Xytis Pharmaceuticals.
- 12.20 Networking Lunch
- 1.50 DECREASING THE PLACEBO RESPONSE IN ANTIDEPRESSANT CLINICAL TRIALS
- Implications of the placebo response in depression research
- Tonmoy Sharma, Director, Clinical Neuroscience Research centre .
- 2.30 MRNA EDITING: NEW TARGET IN PSYCHIATRIC DISORDERS
- Discovery and development of therapeutic and diagnostic innovative applications of RNA receptor editing
- What is mRNA editing?
- Editing: a key target
- ·Biocortech EDIT technology
- Editing as a signature
- Therapeutics and diagnostics perspectives
- Dinah Weissmann, CEO, Biocortech.
- 3.10 Afternoon Tea
- 3.30 LIGHT THERAPY AND SLEEP DEPRIVATION FOR DEPRESSION
- Professor Anna Wirz-Justice, Professor of Psychiatry, UNIVERSITY OF BASEL.
- 4.10 GLYCOGEN SYNTHASE KINASE-3 ß
- A target for the treatment of mood disorders
- Lithium salts as medication
- Lithium molecular targets
- GSK-3 mediating signalling
- GSK3 and mood disorders
- GSK3 inhibitors
- Dr Miguel Medina, Director, Drug Discovery, Neuropharma.
- 4.50 Chairman’s Closing Remarks and Close of Day One
- Day Two
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California.
- 9.10 NEW COLLABORATIVE OUTCOME MEASURES IN EVALUATING DEPRESSION IN CLINICAL TRIALS
- A collaboration of industry, academia, and government
- Learn about new methodologies in developing outcome measures in depression
- Review data generated by this approach
- Discuss implications for other disorders
- Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California.
- 9.50 IMPROVING CLINICAL TRIAL DESIGN
- Novel clinical development strategies
- Risk management Plans and post registration considerations- what should be addressed for depression and anxiety?
- Paediatric investigation plans
- Dr Jill Rasmussen, Director, Psi-napse.
- 10.30 Morning Coffee
- 10.50 PANEL DISCUSSION - THE LACK OF NOVEL TREATMENTS APPROVED FOR THE TREATMENT OF DEPRESSION
- Can animal models, imaging, translational medicine and novel study design really help us?
- Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California.
- Dr Andrew Harkin, Director of Neuropsychopharmacology Research, Trinity College Dublin.
- Dr Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School.
- Lee E Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth.
- 11.50 TOPIC TBC
- Dr Geoffrey Burnstock, President, Autonomic Neuroscience Centre, Department of Anatomy and Developmental Biology, Royal Free and University College Medical School.
- 12.30 Networking Lunch
- 1.30 BIOMARKER IDENTIFICATION VIA MONITORING TECHNOLOGIES
- Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring , Johnson & Johnson.
- 2.10 IMPROVING THE LINK BETWEEN CLINICAL AND PRE-CLINICAL DATA
- Dr Irina Antonijevic, Director, Translational Research, Lundbeck, Inc..
- 3.10 IMPROVING TRANSLATIONAL MEDICINE AND ANIMAL MODELS
- Development of sophisticated translational tools
- Dr Andrew Harkin, Director of Neuropsychopharmacology Research, Trinity College Dublin.
- 3.50 NOVEL APPROACHES TO THE INVESTIGATION OF DRUG ACTION IN ANIMAL MODELS OF MENTAL DISORDERS
- Review of the application of pharmacological MRI (phMRI) to study the action of psychoactive drugs, including SSRIs, in rodents
- Improving the translational value of information obtained using animal models of mental disorders
- Adopting methodologies that are common to both animal and human studies
- fMRI can be used in both and make it possible to identify the brain regions involved in drug action
- New information about the neural pathways involved in drug action
- Dr Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School.
- 4.30 Chairman’s Closing Remarks and End of Conference
AbstractThe SMi Group's 3rd Annual Depression & Anxiety Conference will bring together the key industry leaders to discuss the current and future opportunities within psychopharmacotherapy.
This is a must-attend event for all those involved in addressing the growing challenges of diagnosing and treating the spectrum of distinct disorders.
This two day intensive forum will help you learn more about:
- Drug development and new compounds: examine the emerging developments from the psychopharmaceutical drug pipelines and investigate the challenges that must be considered by the psychopharmacological community
- Avoiding trial failure and improving study design: discover novel approaches specific to designing clinical studies for patients with mood disorders
- Psychogenomics: hear about how genetics could provide the key to producing a truly individualised therapy system, and how the latest discoveries could help salvage previously doomed drug candidates
- Translational issues in mood disorders: using translational methods to overcome traditional obstacles while developing new treatments for mood disorders
- New targets and Biomarkers in lead discovery: identify new targets and improve biomarker selections to predict the effectiveness and safety of drugs for the treatment of depression
The conference features an excellent opportunity to hear from an international panel of experts, including:
- Dr Lee E. Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth
- Dr Tanya Ramey, Clinical Lead, Neurosciences, Pfizer
- Dr Pim Drinkenburg, Research Fellow, Head Biomonitoring Centre of Expertise Europe, Johnson & Johnson
- Dr Zhengming Chen, Senior Director, Chemistry, DOV Pharmaceuticals
- Dr Vincent F. Simmon, President & CEO, Xytis Pharmaceuticals
- Dr Dinah Weissman, CEO, Biocortech
- Dr Miguel Medina, Drug Discovery Director, Neuropharma
- Dr Jill Rasmussen, Director, Psynapse
- Prof Tonmoy Sharma, Director, Clinical Neuroscience Research Centre
- Dr Andrew Harkin, Director, Neuropsychopharmacology Research, Trinity College Institute if Neuroscience, Trinity College, Dublin
- Professor Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School
Who should attend Depression & Anxiety 2007?
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:
- Behavioural Neuroscience
- CNS
- Biomonitoring
- Clinical Development
- Scientific Services
- Research & Development
- Psychopharmacology Research
- Clinical Psychology
- Clinical Pharmacodynamics
- Marketing
- Portfolio Management
- Marketing
- Project management
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
